Cat. No：GM-C14346
Product：Tango-H_CXCR6 CHO-K1 Cell Line
Cat. No：GM-C14346
Product：Tango-H_CXCR6 CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+100 μg/mL Hygromycin+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：F12K+1% FBS+1% P.S
G protein-coupled receptors (GPCRs) family is the largest membrane protein family in humans and serves as important targets for many drugs. With over 800 members, nearly 400 can be considered as drug targets. Drugs targeting GPCRs account for 34% of all FDA-approved drugs, mainly used for conditions such as hypertension, diabetes, obesity, allergies, Alzheimer's disease, and various central nervous system disorders.
GPCR activation involves two signaling pathways: G protein-dependent and G protein-independent pathways. In the G protein-dependent pathway, GPCR couples with intracellular G proteins (Gi/Go, Gs, Gq, and G12/G13), activating or inhibiting signals through detecting second messengers like calcium flow, cyclic adenosine monophosphate (cAMP), etc. The G protein-independent pathway involves GPCR inducing β-arrestin translocation, which is separate from G protein receptor signals and can be used for orphan receptors, detecting activation of G protein-independent pathways through β-arrestin.
CXCL16 is the ligand for CXCR6 and regulates cancer metastasis and invasion. CXCL16 and CXCR6 may serve as markers for cancer occurring in inflammatory environments, mediating inflammation-promoting tumor growth directly and inducing migration and proliferation of tumor-associated leukocytes.
Tango-H_CXCR6 CHO-K1 Cell Line uses CHO-K1 cells, infected with lentivirus, to establish Tango CXCR6 reporter gene cell lines via Tango technology. When CXCL16 activates the CXCR6 Arrestin pathway, Arrestin cleaves a protein carrying transcriptional activation elements, translocating these elements to the nucleus, activating the luciferase reporter gene. Luciferase reporter gene readings indicate the effectiveness of the signaling pathway activation, used for testing the activity of antibodies targeting CXCL16/CXCR6 functionality.
Cat. No：GM-C14346
Product：Tango-H_CXCR6 CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+100 μg/mL Hygromycin+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：F12K+1% FBS+1% P.S
G protein-coupled receptors (GPCRs) family is the largest membrane protein family in humans and serves as important targets for many drugs. With over 800 members, nearly 400 can be considered as drug targets. Drugs targeting GPCRs account for 34% of all FDA-approved drugs, mainly used for conditions such as hypertension, diabetes, obesity, allergies, Alzheimer's disease, and various central nervous system disorders.
GPCR activation involves two signaling pathways: G protein-dependent and G protein-independent pathways. In the G protein-dependent pathway, GPCR couples with intracellular G proteins (Gi/Go, Gs, Gq, and G12/G13), activating or inhibiting signals through detecting second messengers like calcium flow, cyclic adenosine monophosphate (cAMP), etc. The G protein-independent pathway involves GPCR inducing β-arrestin translocation, which is separate from G protein receptor signals and can be used for orphan receptors, detecting activation of G protein-independent pathways through β-arrestin.
CXCL16 is the ligand for CXCR6 and regulates cancer metastasis and invasion. CXCL16 and CXCR6 may serve as markers for cancer occurring in inflammatory environments, mediating inflammation-promoting tumor growth directly and inducing migration and proliferation of tumor-associated leukocytes.
Tango-H_CXCR6 CHO-K1 Cell Line uses CHO-K1 cells, infected with lentivirus, to establish Tango CXCR6 reporter gene cell lines via Tango technology. When CXCL16 activates the CXCR6 Arrestin pathway, Arrestin cleaves a protein carrying transcriptional activation elements, translocating these elements to the nucleus, activating the luciferase reporter gene. Luciferase reporter gene readings indicate the effectiveness of the signaling pathway activation, used for testing the activity of antibodies targeting CXCL16/CXCR6 functionality.
